SCIENTIFIC **Reports**

Received: 16 June 2016 Accepted: 28 September 2016 Published: 13 October 2016

OPEN Comparison of overall survival in patients with unresectable hepatic metastases with or without transarterial chemoembolization: A **Propensity Score Matching Study**

F. Y. Wang¹, W. Meng², Y. Li³, T. Li⁴ & C. Y. Qin^{4,5}

Transarterial chemoembolization (TACE) has mostly been used in hypervascular tumours such as hepatocellular carcinoma, and may be an effective palliative treatment in patients with metastatic liver cancer. Our goal is to determine whether TACE increases overall survival (OS) of in patients with liver metastases. The retrospective cohort study included 171 patients with liver metastases diagnosed between 2001 and 2015. OS was compared between the TACE and non-TACE groups after propensity score matching to reduce the effects of selection bias and potential confounders. Multivariate analysis was conducted to confirm the confounding factors with OS. After excluding 43 patients, 128 patients were analysed and among thses 64 patients (50%) were included in the TACE group. In the propensity score matched cohort (42 pairs), the OS was non-significantly longer in the TACE group than in the non-TACE group (p = 0.789). Multivariate analysis revealed that international normalized ratio (INR) (HR 0.058, 95%CI: [0.005, 0.681]; p = 0.023) and Radiofrequency ablation (RFA) (HR 3.054, 95%CI: [1.418, 6.579]; p = 0.004) were independent risk factors for OS in patients with unresectable liver metastases. There were no significant differences in patients with unresectable liver metastases with or without TACE. INR and RFA can significantly affect OS in patients with unresectable liver metastases.

Metastatic liver disease represents a common challenge in oncology. The liver is the most common site of metastases that arise from gastrointestinal malignancies¹; and, other primary sites of origin, including breast, lung, pancreas, and endometrial carcinomas. Local therapy for liver metastases from primary locations, such as breast, lung, gastric or pancreatic cancer may have little success due to the presence of extrahepatic disease. For colorectal cancer, hepatic resection in selected patients can result in 5-year survival rates of 20% to 44-45%^{2,3}. However, compared with the number of patients demonstrating liver metastasis, the number of resectable candidates is limited.

In most cases, liver metastases are treated with oral or intravenous chemotherapy. Transarterial chemoembolization (TACE), the combination of the injection of a drug and embolic material, has mostly been used in hypervascular tumours such as hepatocellular carcinoma⁴, and may be an effective palliative treatment in patients with metastatic liver cancer.

Propensity score matching⁵ is a statistical technique in which a treatment case is matched with one or more control cases based on each case's propensity score. This matching can help strengthen causal arguments in quasi-experimental and observational studies by reducing selection bias.

¹Department of gastroenterology and hepatology, Shandong Provincial Hospital, Shandong University, Shandong, 250100, China. ²Department of ECG, Qilu hospital affiliated to Shandong University, Shandong, 250012, China. ³Department of Intensive care unit, Qilu hospital affiliated to Shandong University, Shandong, 250012, China. ⁴Department of Gastroenterology and Hepatology, Shandong Province Hospital Affiliated to Shandong University, Shandong, 250021, China. ⁵Shandong provincial engineering and technological research center for liver diseases prevention and control, Shandong, 250021, China. Correspondence and requests for materials should be addressed to C.Y.Q. (email: ginchengyong@hotmail.com)

VariablesTACE groupgrouppralueAge (years)60.44 ± 10.6559.34 ± 11.920.585Gender, male41 (64.1%)41 (64.1%)1Primary tumour site710.9%)8 (12.5%)0.688Stomach17 (26.6%)17 (26.6%)0Endometrium11 (1.6%)0Chorion11 (1.6%)0Colorectum19 (29.7%)17 (26.6%)Bile ducts4 (6.3%)0Duodenum3 (4.7%)2 (3.1%)Bile ducts11 (1.6%)2 (3.1%)Duodenum3 (4.7%)2 (3.1%)Others10 (1.6%)3 (4.7%)Outhenum3 (4.7%)3 (4.7%)Outhenum3 (4.7%)3 (4.7%)Others4 (6.3%)10 (15.6%)Others4 (6.3%)10 (15.6%)Others4 (6.3%)10 (15.6%)One4 (6.3%)10 (15.6%)One4 (6.3%)10 (15.6%)One4 (6.3%)10 (15.6%)One2 (3.1%)3 (4.7%)One4 (6.3%)10 (15.6%)One4 (6.3%)10 (15.6%)One15 (23.4%)5 (7.8%)One4 (6.3%)10 (15.6%)One<					
Gender, male 41 (64.1%) 41 (64.1%) 1 Primary tumour site Pancreas 7 (10.9%) 8 (12.5%) 0.688 Stomach 17 (26.6%) 17 (26.6%) 17 (26.6%) Endometrium 1 (1.6%) 0 0 Chorion 1 (1.6%) 0 1 Ovaries 2 (3.1%) 2 (3.1%) 2 Bile ducts 4 (6.3%) 6 (9.4%) 1 Lung 4 (6.3%) 6 (9.4%) 1 Duodenum 3 (4.7%) 2 (3.1%) 2 Duodenum 3 (4.7%) 2 (3.1%) 1 Ores 1 (1.6%) 3 (4.7%) 2 Outhers 4 (6.3%) 10 (15.6%) 0.044 Two 2 (3.1%) 3 (4.7%) 1 Others 4 (6.3%) 10 (15.6%) 0.044 Two 2 (3.1%) 3 (4.7%) 1 Unknown 15 (23.4%) 5 (7.8%) 0 Other organs 12 (18.8%) 16 (25%) 0.14 <t< th=""><th>Variables</th><th>TACE group</th><th></th><th><i>p</i> value</th></t<>	Variables	TACE group		<i>p</i> value	
Primary tumour site Pancreas 7 (10.9%) 8 (12.5%) 0.688 Stomach 17 (26.6%) 17 (26.6%) 17 Endometrium 1 (1.6%) 0 0 Chorion 1 (1.6%) 0 1 Colorectum 19 (29.7%) 17 (26.6%) 1 Ovaries 2 (3.1%) 2 (3.1%) 1 Bile ducts 4 (6.3%) 0 1 Lung 4 (6.3%) 6 (9.4%) 1 Duodenum 3 (4.7%) 2 (3.1%) 1 Duodenum 3 (4.7%) 2 (3.1%) 1 Oesophagus 1 (1.6%) 3 (4.7%) 1 Others 4 (6.3%) 10 (15.6%) 0.044 Two 2 (3.1%) 3 (4.7%) 1 Other organs 15 (23.4%) 5 (7.8%) 1 Unknown 15 (23.4%) 16 (25%) 0.145 Other organs 12 (18.8%) 16 (25%) 0.141 Unknown 43 (67.2%) 32 (50%) 1 <	Age (years)	60.44 ± 10.65	59.34 ± 11.92	0.585	
Pancreas7 (10.9%)8 (12.5%)0.688Stomach17 (26.6%)17 (26.6%)1Endometrium1 (1.6%)00Chorion1 (1.6%)01Colorectum19 (29.7%)17 (26.6%)1Ovaries2 (3.1%)2 (3.1%)1Bile ducts4 (6.3%)01Lung4 (6.3%)6 (9.4%)1Kidney02 (3.1%)1Duodenum3 (4.7%)2 (3.1%)1Breast1 (1.6%)2 (3.1%)1Oesophagus1 (1.6%)3 (4.7%)1Others4 (6.3%)4 (6.3%)10 (15.6%)0.044Two2 (3.1%)3 (4.7%)1One4 (6.3%)10 (15.6%)0.044Two2 (3.1%)3 (4.7%)1More43 (67.2%)46 (71.9%)1Unknown15 (23.4%)16 (25%)0.145Other organs12 (18.8%)16 (25%)0.145Other organs12 (18.8%)16 (25%)0.344CHD7 (10.9%)5 (7.8%)0.344CHD7 (10.9%)5 (7.8%)0.344Ghid-Pugh case5.25 ± 0.695.13 ± 0.490.239Hepatitis1 (1.6%)00.043Child-Pugh case5.25 ± 0.695.13 ± 0.490.239Child-Pugh case5.25 ± 0.695.13 ± 0.490.239Child-Pugh case5.75.%)2.31.%)0.498B5 (7.8%)2 (3.1%)0.498 <tr< td=""><td>Gender, male</td><td>41 (64.1%)</td><td>41 (64.1%)</td><td>1</td></tr<>	Gender, male	41 (64.1%)	41 (64.1%)	1	
Stomach 17 (26.6%) 17 (26.6%) Endometrium 1 (1.6%) 0 Chorion 1 (1.6%) 0 Colorectum 19 (29.7%) 17 (26.6%)	Primary tumour site				
Endometrium 1 (1.6%) 0 Chorion 1 (1.6%) 0 Colorectum 19 (29.7%) 17 (26.6%) Ovaries 2 (3.1%) 2 (3.1%) Bile ducts 4 (6.3%) 0 Lung 4 (6.3%) 6 (9.4%) Kidney 0 2 (3.1%) Duodenum 3 (4.7%) 2 (3.1%) Breast 1 (1.6%) 3 (4.7%) Oesophagus 1 (1.6%) 3 (4.7%) Gallbladder 0 1 (1.6%) Others 4 (6.3%) 4 (6.3%) Numbers of hepatic metases 0 0.044 Two 2 (3.1%) 3 (4.7%) More 4 (6.3%) 10 (15.6%) 0.044 Two 2 (3.1%) 3 (4.7%) 10 Unknown 15 (23.4%) 5 (7.8%) 0 Other transfers 1 16 (25%) 0.145 Unknown 43 (67.2%) 32 (50%) 1 Hypertension 14 (21.9%) 1 1	Pancreas	7 (10.9%)	8 (12.5%)	0.688	
Chorion 1 (1.6%) 0 Colorectum 19 (29.7%) 17 (26.6%)	Stomach	17 (26.6%)	17 (26.6%)		
Colorectum19 (29.7%)17 (26.6%)Ovaries2 (3.1%)2 (3.1%)Bile ducts4 (6.3%)0Lung4 (6.3%)6 (9.4%)Kidney02 (3.1%)Duodenum3 (4.7%)2 (3.1%)Breast1 (1.6%)2 (3.1%)Oesophagus1 (1.6%)3 (4.7%)Gallbladder01 (1.6%)Others4 (6.3%)4 (6.3%)Numbers of hepatic metastes01 (1.6%)One4 (6.3%)10 (15.6%)0.044Two2 (3.1%)3 (4.7%)More43 (67.2%)46 (71.9%)Unknown15 (23.4%)5 (7.8%)Other transfers12 (18.8%)16 (25%)Unknown43 (67.2%)32 (50%)Hypertension14 (21.9%)14 (21.9%)Hypertension14 (21.9%)14 (21.9%)Ibibetes7 (10.9%)4 (6.3%)0.344CHD7 (10.9%)5 (7.8%)0.269Hepatitis1 (1.6%)00.043Child-Pugh classificationus20 (31.3%)26 (40.6.90%)0.269Hepatitis1 (1.6%)00.043Child-Pugh score5.25 \pm 0.695.13 \pm 0.490.239Child-Pugh score5.25 \pm 0.695.13 \pm 0.490.239Child-Pugh score5.25 \pm 0.695.13 \pm 0.490.239Child-Pugh score5.7.8%)2 (3.1%)0.498TBIL16.53 \pm 16.4718.95 \pm 32.470.596Albunin39.87 \pm 5.5638	Endometrium	1 (1.6%)	0		
Ovaries $2 (3.1\%)$ $2 (3.1\%)$ Bile ducts $4 (6.3\%)$ 0 Lung $4 (6.3\%)$ $6 (9.4\%)$ Kidney 0 $2 (3.1\%)$ Duodenum $3 (4.7\%)$ $2 (3.1\%)$ Breast $1 (1.6\%)$ $2 (3.1\%)$ Breast $1 (1.6\%)$ $2 (3.1\%)$ Oesophagus $1 (1.6\%)$ $3 (4.7\%)$ Gallbladder 0 $1 (1.6\%)$ Others $4 (6.3\%)$ $4 (6.3\%)$ Numbers of hepatic metastasesOne $4 (6.3\%)$ $10 (15.6\%)$ One $4 (6.3\%)$ $10 (15.6\%)$ Unknown $15 (23.4\%)$ $5 (7.8\%)$ Unknown $15 (23.4\%)$ $5 (7.8\%)$ Other transfers $12 (18.8\%)$ $16 (25\%)$ Unknown $43 (67.2\%)$ $32 (50\%)$ Hypertension $14 (21.9\%)$ $14 (21.9\%)$ Hypertension $14 (21.9\%)$ $14 (21.9\%)$ Ibiabetes $7 (10.9\%)$ $5 (7.8\%)$ Other organs $12 (18.8\%)$ $16 (25\%)$ Unknown $43 (67.2\%)$ $32 (50\%)$ Hypertension $14 (21.9\%)$ $14 (21.9\%)$ I $11 (1.6\%)$ 0 Other organs $12 (18.8\%)$ $16 (25\%)$ Unknown $4 (6.3\%)$ 0.344 CHD $7 (10.9\%)$ $5 (7.8\%)$ Other organs $12 (18.9\%)$ $14 (21.9\%)$ Ibiabetes $7 (10.9\%)$ $5 (7.8\%)$ Other organs $12 (18.9\%)$ $10 (15.69\%)$ Diabetes $7 (10.9\%)$ $5 (7.8\%)$ Other organs $12 (18.9\%)$ 10	Chorion	1 (1.6%)	0		
Bile ducts4 (6.3%)0Lung4 (6.3%)6 (9.4%)Kidney02 (3.1%)Duodenum3 (4.7%)2 (3.1%)Breast1 (1.6%)2 (3.1%)Oesophagus1 (1.6%)3 (4.7%)Gallbladder01 (1.6%)Others4 (6.3%)4 (6.3%)Others4 (6.3%)10 (15.6%)One4 (6.3%)10 (15.6%)One4 (6.3%)10 (15.6%)One4 3 (67.2%)46 (71.9%)Unknown15 (23.4%)5 (7.8%)Other ransfers10 (15.6%)0.145Other organs12 (18.8%)16 (25%)Unknown43 (67.2%)32 (50%)Unknown43 (67.2%)32 (50%)Hypertension14 (21.9%)14Diabetes7 (10.9%)5 (7.8%)Other organs12 (18.8%)16 (25%)Unknown43 (67.2%)32 (50%)Hypertension14 (21.9%)14Diabetes7 (10.9%)5 (7.8%)Other organs12 (18.8%)16 (25%)Hypertension14 (21.9%)14Diabetes7 (10.9%)5 (7.8%)Other organs12 (18.8%)16 (25%)Unknown43 (67.2%)32 (50%)Hypertension14 (21.9%)14Diabetes7 (10.9%)5 (7.8%)Other organs12 (18.8%)16 (25%)Other organs12 (18.8%)16 (25%)Other organs13 (1.6%)0Other organs14 (21.9%)	Colorectum	19 (29.7%)	17 (26.6%)		
Lung4 (6.3%) $6 (9.4\%)$ Kidney0 $2 (3.1\%)$ Duodenum $3 (4.7\%)$ $2 (3.1\%)$ Breast $1 (1.6\%)$ $2 (3.1\%)$ Oesophagus $1 (1.6\%)$ $3 (4.7\%)$ Gallbladder0 $1 (1.6\%)$ $3 (4.7\%)$ Others $4 (6.3\%)$ $4 (6.3\%)$ 0.044 Two $2 (3.1\%)$ $3 (4.7\%)$ More $4 3 (67.2\%)$ $46 (71.9\%)$ 0.044 Two $2 (3.1\%)$ $3 (4.7\%)$ Unknown $15 (23.4\%)$ $5 (7.8\%)$ 0.145 Other transfers $16 (25\%)$ 0.145 Unknown $43 (67.2\%)$ $32 (50\%)$ 16 Unknown $43 (67.2\%)$ $32 (50\%)$ 11 Diabetes $7 (10.9\%)$ $14 (21.9\%)$ 11 Other organs $12 (18.8\%)$ $16 (25\%)$ 0.344 CHD $7 (10.9\%)$ $5 (7.8\%)$ 0.544 Smoking $20 (31.3\%)$ $26 (40.6.90\%)$ 0.269 Hepatitis $1 (1.6\%)$ 0 0.433 Child-Pugh score 5.25 ± 0.69 5.13 ± 0.49 0.239 Child-Pugh score 5.25 ± 0.69 5.13 ± 0.49 0.239 Child-Pugh score $5 (7.8\%)$ $2 (3.1\%)$ 0.498 TBIL 16.53 ± 16.47 18.95 ± 32.47 0.596 Albumin 39.87 ± 5.56 38.71 ± 6.26 0.271 PT 13.51 ± 14.61 12.09 ± 1.74 0.44 APTT 40.05 ± 24.27 30.56 ± 4.99 0.003 INR 1.02 ± 0.11 1.03 ± 0.11	Ovaries	2 (3.1%)	2 (3.1%)		
Kidney02 (3.1%)Duodenum3 (4.7%)2 (3.1%)Breast1 (1.6%)2 (3.1%)Oesophagus1 (1.6%)3 (4.7%)Gallbladder01 (1.6%)Others4 (6.3%)4 (6.3%)Numbers of hepatic metatases010 (15.6%)One4 (6.3%)10 (15.6%)0.044Two2 (3.1%)3 (4.7%)More43 (67.2%)46 (71.9%)Unknown15 (23.4%)5 (7.8%)Other ransfers011 (16%)Unknown13 (67.2%)32 (50%)Unknown43 (67.2%)32 (50%)Unknown43 (67.2%)32 (50%)Unknown43 (67.2%)32 (50%)Unknown43 (67.2%)32 (50%)Unknown43 (67.2%)32 (50%)Unknown43 (67.2%)32 (50%)Hypertension14 (21.9%)11Diabetes7 (10.9%)5 (7.8%)0.344CHD7 (10.9%)5 (7.8%)0.269Hepatitis1 (1.6%)00.043Child-Pugh score5.25 \pm 0.695.13 \pm 0.490.239Child-Pugh score5.25 \pm 0.695.13 \pm 0.490.239Child-Pugh classification11.653 \pm 16.4718.95 \pm 32.470.596A59 (92.2%)62 (96.9%)11AST33.80 \pm 19.5237.09 \pm 33.500.498TBIL16.53 \pm 16.4718.95 \pm 32.470.596Albumin39.87 \pm 5.5638.71 \pm 6.26 <t< td=""><td>Bile ducts</td><td>4 (6.3%)</td><td>0</td><td></td></t<>	Bile ducts	4 (6.3%)	0		
Duodenum $3 (4.7\%)$ $2 (3.1\%)$ Breast $1 (1.6\%)$ $2 (3.1\%)$ Breast $1 (1.6\%)$ $2 (3.1\%)$ Oesophagus $1 (1.6\%)$ $3 (4.7\%)$ Gallbladder 0 $1 (1.6\%)$ Others $4 (6.3\%)$ $4 (6.3\%)$ Numbers of hepatic metastases 0 $1 (1.6\%)$ One $4 (6.3\%)$ $10 (15.6\%)$ 0.044 Two $2 (3.1\%)$ $3 (4.7\%)$ 0.044 Two $2 (3.1\%)$ $5 (7.8\%)$ 0.145 Other transfers U $16 (25\%)$ 0.145 Unknown $43 (67.2\%)$ $32 (50\%)$ 1 Diabetes $7 (10.9\%)$ $5 (7.8\%)$ 0.344 CHD $7 (10.9\%)$ $5 (7.8\%)$ 0.544 Smoking $20 (31.3\%)$ $26 (40.6.90\%)$ 0.269 Hepatitis $1 (1.6\%)$ 0 0.043 Child-Pugh score 5.25 ± 0.69 5.13 ± 0.49 0.239 Child-Pugh score $5 (7.8\%)$ $2 (3.1\%)$ 0.498 TBIL 16.53 ± 16.47 18.95 ± 32.47 0.596 <t< td=""><td>Lung</td><td>4 (6.3%)</td><td>6 (9.4%)</td><td></td></t<>	Lung	4 (6.3%)	6 (9.4%)		
Breast1 (1.6%)2 (3.1%)Oesophagus1 (1.6%)3 (4.7%)Gallbladder01 (1.6%)Others4 (6.3%)4 (6.3%)Numbers of hepatic metstasesOne4 (6.3%)10 (15.6%)0.044Two2 (3.1%)3 (4.7%)10More43 (67.2%)46 (71.9%)10Unknown15 (23.4%)5 (7.8%)10Other transfers12 (18.8%)16 (25%)0.145Other organs12 (18.8%)16 (25%)11Other organs12 (18.8%)16 (25%)11Diabetes7 (10.9%)32 (50%)11Diabetes7 (10.9%)5 (7.8%)0.344CHD7 (10.9%)5 (7.8%)0.544Smoking20 (31.3%)26 (40.6.90%)0.269Hepatitis1 (1.6%)00.043Child-Pugh score 5.25 ± 0.69 5.13 ± 0.49 0.239Child-Pugh classification 33.80 ± 19.52 37.09 ± 33.50 0.498TBIL16.53 \pm 16.4718.95 \pm 32.470.596AST33.80 \pm 19.5237.09 \pm 33.500.498TBIL16.53 \pm 16.4718.95 \pm 32.470.596Albumin39.87 \pm 5.5638.71 \pm 6.260.271PT13.51 \pm 14.6112.09 \pm 1.740.44APTT40.05 \pm 24.2730.56 \pm 4.990.003INR1.02 \pm 0.111.03 \pm 0.110.522Ascites2 (3.1%)3 (4.7%)0.648	Kidney	0	2 (3.1%)		
Oesophagus1 (1.6%)3 (4.7%)Gallbladder01 (1.6%)Others4 (6.3%)4 (6.3%)Numbers of hepatic metastasesOne4 (6.3%)10 (15.6%)0.044Two2 (3.1%)3 (4.7%)More43 (67.2%)46 (71.9%)Unknown15 (23.4%)5 (7.8%)Other transfersLymph gland9 (14.1%)16 (25%)Other organs12 (18.8%)16 (25%)Unknown43 (67.2%)32 (50%)Hypertension14 (21.9%)11Diabetes7 (10.9%)5 (7.8%)0.344CHD7 (10.9%)5 (7.8%)0.544Smoking20 (31.3%)26 (40.6.90%)0.269Hepatitis1 (1.6%)00.043Child-Pugh score 5.25 ± 0.69 5.13 ± 0.49 0.239Child-Pugh score5 (7.8%)2 (3.1%)1A59 (92.2%) $62 (96.9\%)$ 0.498TBIL16.53 \pm 16.4718.95 \pm 32.470.596Albumin39.87 \pm 5.56 38.71 ± 6.26 0.271PT13.51 \pm 14.6112.09 \pm 1.740.44APTT40.05 \pm 24.27 30.56 ± 4.99 0.003INR 1.02 ± 0.11 1.03 ± 0.11 0.522Ascites2 (3.1%)3 (4.7%)0.648	Duodenum	3 (4.7%)	2 (3.1%)		
Gallbadder01 (1.6%)Others4 (6.3%)4 (6.3%)Numbers of hepatic metastasesOne4 (6.3%)10 (15.6%)0.044Two2 (3.1%)3 (4.7%)0More43 (67.2%)46 (71.9%)0Unknown15 (23.4%)5 (7.8%)0Other transfers16 (25%)0.145Other organs12 (18.8%)16 (25%)0.145Other organs12 (18.8%)16 (25%)0.145Other organs12 (18.8%)14 (21.9%)1Diabetes7 (10.9%)5 (7.8%)0.544Smoking20 (31.3%)26 (40.6.90%)0.269Hepatitis1 (1.6%)00.043Child-Pugh score5.25 \pm 0.695.13 \pm 0.490.239Child-Pugh classification33.80 \pm 19.5237.09 \pm 33.500.498TBIL16.53 \pm 16.4718.95 \pm 32.470.596Albumin39.87 \pm 5.5638.71 \pm 6.260.271PT13.51 \pm 14.6112.09 \pm 1.740.44APTT40.05 \pm 24.2730.56 \pm 4.990.003INR1.02 \pm 0.111.03 \pm 0.110.522Ascites2 (3.1%)3 (4.7%)0.648	Breast	1 (1.6%)	2 (3.1%)		
Others4 (6.3%)4 (6.3%) 4 (6.3%)Numbers of hepatic metassesOne4 (6.3%)10 (15.6%)0.044Two2 (3.1%)3 (4.7%) 3 More43 (67.2%)46 (71.9%) 1 Unknown15 (23.4%)5 (7.8%) 1 Other transfers 12 (18.8%)16 (25%) 0.145 Other organs12 (18.8%)16 (25%) 1 Unknown43 (67.2%)32 (50%) 1 Diabetes7 (10.9%)14 (21.9%) 1 Diabetes7 (10.9%)5 (7.8%) 0.344 CHD7 (10.9%)5 (7.8%) 0.544 Smoking20 (31.3%)26 (40.6.90%) 0.269 Hepatitis1 (1.6%)0 0.043 Child-Pugh score 5.25 ± 0.69 5.13 ± 0.49 0.239 Child-Pugh classificatio- 33.80 ± 19.52 37.09 ± 33.50 0.498 TBIL 16.53 ± 16.47 18.95 ± 32.47 0.596 Albumin 39.87 ± 5.56 38.71 ± 6.26 0.271 PT 13.51 ± 14.61 12.09 ± 1.74 0.44 APTT 40.05 ± 24.27 30.56 ± 4.99 0.003 INR 1.02 ± 0.11 1.03 ± 0.11 0.522 Ascites 2 (3.1%) 3 (4.7%) 0.648	Oesophagus	1 (1.6%)	3 (4.7%)		
Numbers of hepatic metastasesOne4 (6.3%)10 (15.6%)0.044Two2 (3.1%)3 (4.7%)0More43 (67.2%)46 (71.9%)0Unknown15 (23.4%)5 (7.8%)0Other transfersLymph gland9 (14.1%)16 (25%)0.145Other organs12 (18.8%)16 (25%)0.145Unknown43 (67.2%)32 (50%)1Hypertension14 (21.9%)14 (21.9%)1Diabetes7 (10.9%)5 (7.8%)0.544Smoking20 (31.3%)26 (40.6.90%)0.269Hepatitis1 (1.6%)00.043Child-Pugh score5.25 \pm 0.695.13 \pm 0.490.239Child-Pugh classification X 33.80 \pm 19.5237.09 \pm 33.500.498TBIL16.53 \pm 16.4718.95 \pm 32.470.596Albumin39.87 \pm 5.5638.71 \pm 6.260.271PT13.51 \pm 14.6112.09 \pm 1.740.44APTT40.05 \pm 24.2730.56 \pm 4.990.003INR1.02 \pm 0.111.03 \pm 0.110.522Ascites2 (3.1%)3 (4.7%)0.648	Gallbladder	0	1 (1.6%)		
One4 (6.3%)10 (15.6%)0.044Two2 (3.1%)3 (4.7%) $(46 (71.9\%)$ (71.9%) More43 (67.2%)46 (71.9%) (71.9%) Unknown15 (23.4%)5 (7.8%) (71.9%) Other transfers (14.1%) 16 (25%) (14.5%) Uymph gland9 (14.1%)16 (25%) (14.5%) Other organs12 (18.8%)16 (25%) (14.5%) Unknown43 (67.2%)32 (50%) (14.5%) Unknown43 (67.2%)32 (50%) (14.5%) Hypertension14 (21.9%)14 (21.9%) (1.5%) Diabetes7 (10.9%)5 (7.8%) 0.344 CHD7 (10.9%)5 (7.8%) 0.544 Smoking20 (31.3%)26 (40.6.90%) 0.269 Hepatitis1 (1.6%)0 0.043 Child-Pugh score 5.25 ± 0.69 5.13 ± 0.49 0.239 Child-Pugh classification (57.8%) $2 (3.1\%)$ (3.1%) A59 (92.2%) $62 (96.9\%)$ (5.9%) B $5 (7.8\%)$ $2 (3.1\%)$ $(.44)$ AST 33.80 ± 19.52 37.09 ± 33.50 0.498 TBIL 16.53 ± 16.47 18.95 ± 32.47 0.596 Albumin 39.87 ± 5.56 38.71 ± 6.26 0.271 PT 13.51 ± 14.61 12.09 ± 1.74 0.44 APTT 40.05 ± 24.27 30.56 ± 4.99 0.003 INR 1.02 ± 0.11 1.03 ± 0.11 0.522 Ascites $2 (3.1\%)$ $3 (4.7\%)$ 0.648 <td>Others</td> <td>4 (6.3%)</td> <td>4 (6.3%)</td> <td></td>	Others	4 (6.3%)	4 (6.3%)		
Two2 (3.1%)3 (4.7%)More43 (67.2%)46 (71.9%)Unknown15 (23.4%)5 (7.8%)Other transfers I Lymph gland9 (14.1%)16 (25%)Other organs12 (18.8%)16 (25%)Unknown43 (67.2%)32 (50%)Hypertension14 (21.9%)14 (21.9%)Ibiabetes7 (10.9%)5 (7.8%)0.344CHD7 (10.9%)5 (7.8%)0.544Smoking20 (31.3%)26 (40.6.90%)0.269Hepatitis1 (1.6%)00.0433Child-Pugh classification 33.80 ± 19.52 37.09 ± 33.50 0.498B5 (7.8%)2 (3.1%) $2.63.12 \pm 0.47$ 0.596Albumin39.87 \pm 5.5638.71 \pm 6.260.271PT13.51 \pm 14.6112.09 \pm 1.740.44APTT40.05 \pm 24.2730.56 \pm 4.990.003INR1.02 \pm 0.111.03 \pm 0.110.522Ascites2 (3.1%)3 (4.7%)0.648	Numbers of hepatic met	astases			
More43 (67.2%)46 (71.9%)Unknown15 (23.4%)5 (7.8%)Other transfersLymph gland9 (14.1%)16 (25%)Other organs12 (18.8%)16 (25%)Unknown43 (67.2%)32 (50%)Unknown43 (67.2%)32 (50%)Hypertension14 (21.9%)14 (21.9%)Diabetes7 (10.9%)4 (6.3%)0.344CHD7 (10.9%)5 (7.8%)0.544Smoking20 (31.3%)26 (40.6.90%)0.269Hepatitis1 (1.6%)00.043Child-Pugh score5.25 \pm 0.695.13 \pm 0.490.239Child-Pugh classification 33.80 ± 19.52 37.09 \pm 33.500.498TBIL16.53 \pm 16.4718.95 \pm 32.470.596Albumin39.87 \pm 5.5638.71 \pm 6.260.271PT13.51 \pm 14.6112.09 \pm 1.740.44APTT40.05 \pm 24.2730.56 \pm 4.990.003INR1.02 \pm 0.111.03 \pm 0.110.522Ascites2 (3.1%)3 (4.7%)0.648	One	4 (6.3%)	10 (15.6%)	0.044	
Unknown $15 (23.4\%)$ $5 (7.8\%)$ Other transfersLymph gland $9 (14.1\%)$ $16 (25\%)$ 0.145 Other organs $12 (18.8\%)$ $16 (25\%)$ 1 Unknown $43 (67.2\%)$ $32 (50\%)$ 1 Hypertension $14 (21.9\%)$ $14 (21.9\%)$ 1 Diabetes $7 (10.9\%)$ $4 (6.3\%)$ 0.344 CHD $7 (10.9\%)$ $5 (7.8\%)$ 0.544 Smoking $20 (31.3\%)$ $26 (40.6.90\%)$ 0.269 Hepatitis $1 (1.6\%)$ 0 0.043 Child-Pugh score 5.25 ± 0.69 5.13 ± 0.49 0.239 Child-Pugh classification 33.80 ± 19.52 37.09 ± 33.50 0.498 TBIL 16.53 ± 16.47 18.95 ± 32.47 0.596 Albumin 39.87 ± 5.56 38.71 ± 6.26 0.271 PT 13.51 ± 14.61 12.09 ± 1.74 0.44 APTT 40.05 ± 24.27 30.56 ± 4.99 0.003 INR 1.02 ± 0.11 1.03 ± 0.11 0.522 Ascites $2 (3.1\%)$ $3 (4.7\%)$ 0.648	Two	2 (3.1%)	3 (4.7%)		
Other transfers I 16 (25%) 0.145 Lymph gland 9 (14.1%) 16 (25%) 0.145 Other organs 12 (18.8%) 16 (25%) 1 Unknown 43 (67.2%) 32 (50%) 1 Hypertension 14 (21.9%) 14 (21.9%) 1 Diabetes 7 (10.9%) 4 (6.3%) 0.344 CHD 7 (10.9%) 5 (7.8%) 0.544 Smoking 20 (31.3%) 26 (40.6.90%) 0.269 Hepatitis 1 (1.6%) 0 0.043 Child-Pugh score 5.25 \pm 0.69 5.13 \pm 0.49 0.239 Child-Pugh classification	More	43 (67.2%)	46 (71.9%)		
Lymph gland9 (14.1%)16 (25%)0.145Other organs12 (18.8%)16 (25%)Unknown43 (67.2%)32 (50%)Hypertension14 (21.9%)14 (21.9%)1Diabetes7 (10.9%)4 (6.3%)0.344CHD7 (10.9%)5 (7.8%)0.544Smoking20 (31.3%)26 (40.6.90%)0.269Hepatitis1 (1.6%)00.043Child-Pugh score5.25 \pm 0.695.13 \pm 0.490.239Child-Pugh classificationA59 (92.2%)62 (96.9%)B5 (7.8%)2 (3.1%)AST33.80 \pm 19.5237.09 \pm 33.500.498TBIL16.53 \pm 16.4718.95 \pm 32.470.596Albumin39.87 \pm 5.5638.71 \pm 6.260.271PT13.51 \pm 14.6112.09 \pm 1.740.44APTT40.05 \pm 24.2730.56 \pm 4.990.003INR1.02 \pm 0.111.03 \pm 0.110.522Ascites2 (3.1%)3 (4.7%)0.648	Unknown	15 (23.4%)	5 (7.8%)		
Other organs12 (18.8%)16 (25%)Unknown43 (67.2%)32 (50%)Hypertension14 (21.9%)14 (21.9%)Diabetes7 (10.9%)4 (6.3%)0.344CHD7 (10.9%)5 (7.8%)0.544Smoking20 (31.3%)26 (40.6.90%)0.269Hepatitis1 (1.6%)00.043Child-Pugh score 5.25 ± 0.69 5.13 ± 0.49 0.239Child-Pugh classification $7(8%)$ 2 (3.1%)1A59 (92.2%)62 (96.9%)1B5 (7.8%)2 (3.1%)1AST33.80 ± 19.52 37.09 ± 33.50 0.498TBIL16.53 ± 16.47 18.95 ± 32.47 0.596Albumin39.87 ± 5.56 38.71 ± 6.26 0.271PT13.51 ± 14.61 12.09 ± 1.74 0.44APTT40.05 ± 24.27 30.56 ± 4.99 0.003INR1.02 ± 0.11 1.03 ± 0.11 0.522Ascites2 (3.1%)3 (4.7%)0.648	Other transfers				
Unknown43 (67.2%)32 (50%)Hypertension14 (21.9%)14 (21.9%)1Diabetes7 (10.9%)4 (6.3%)0.344CHD7 (10.9%)5 (7.8%)0.544Smoking20 (31.3%)26 (40.6.90%)0.269Hepatitis1 (1.6%)00.043Child-Pugh score 5.25 ± 0.69 5.13 ± 0.49 0.239Child-Pugh classification 33.80 ± 19.52 37.09 ± 33.50 0.498B5 (7.8%)2 (3.1%) 4.53 ± 16.47 18.95 \pm 32.470.596Albumin 39.87 ± 5.56 38.71 ± 6.26 0.271PT13.51 \pm 14.6112.09 \pm 1.740.44APTT 40.05 ± 24.27 30.56 ± 4.99 0.003INR1.02 \pm 0.111.03 \pm 0.110.522Ascites $2 (3.1\%)$ $3 (4.7\%)$ 0.648	Lymph gland	9 (14.1%)	16 (25%)	0.145	
Hypertension14 (21.9%)14 (21.9%)1Diabetes7 (10.9%)4 (6.3%)0.344CHD7 (10.9%)5 (7.8%)0.544Smoking20 (31.3%)26 (40.6.90%)0.269Hepatitis1 (1.6%)00.043Child-Pugh score 5.25 ± 0.69 5.13 ± 0.49 0.239Child-Pugh classification 4 $59 (92.2\%)$ $62 (96.9\%)$ 62 B5 (7.8%)2 (3.1%) 33.80 ± 19.52 37.09 ± 33.50 0.498 TBIL16.53 \pm 16.4718.95 \pm 32.47 0.596 Albumin39.87 \pm 5.56 38.71 ± 6.26 0.271 PT13.51 \pm 14.6112.09 \pm 1.74 0.444 APTT 40.05 ± 24.27 30.56 ± 4.99 0.003 INR 1.02 ± 0.11 1.03 ± 0.11 0.522 Ascites $2 (3.1\%)$ $3 (4.7\%)$ 0.648	Other organs	12 (18.8%)	16 (25%)		
Diabetes 7 (10.9%) 4 (6.3%) 0.344 CHD 7 (10.9%) 5 (7.8%) 0.544 Smoking 20 (31.3%) 26 (40.6.90%) 0.269 Hepatitis 1 (1.6%) 0 0.043 Child-Pugh score 5.25±0.69 5.13±0.49 0.239 Child-Pugh classification 0 0.43 A 59 (92.2%) 62 (96.9%) A 59 (92.2%) 62 (31.%) AST 33.80±19.52 37.09±33.50 0.498 TBIL 16.53±16.47 18.95±32.47 0.596 Albumin 39.87±5.56 38.71±6.26 0.271 PT 13.51±14.61 12.09±1.74 0.44 APTT 40.05±24.27 30.56±4.99 0.003 INR 1.02±0.11 1.03±0.11 0.522 Ascites 2 (3.1%) 3 (4.7%) 0.648	Unknown	43 (67.2%)	32 (50%)		
CHD 7 (10.9%) 5 (7.8%) 0.544 Smoking 20 (31.3%) 26 (40.6.90%) 0.269 Hepatitis 1 (1.6%) 0 0.043 Child-Pugh score 5.25±0.69 5.13±0.49 0.239 Child-Pugh classification	Hypertension	14 (21.9%)	14 (21.9%)	1	
Smoking 20 (31.3%) 26 (40.6.90%) 0.269 Hepatitis 1 (1.6%) 0 0.043 Child-Pugh score 5.25±0.69 5.13±0.49 0.239 Child-Pugh classification 0 0 0 A 59 (92.2%) 62 (96.9%) A 59 (92.2%) 62 (96.9%) AST 33.80±19.52 37.09±33.50 0.498 TBIL 16.53±16.47 18.95±32.47 0.596 Albumin 39.87±5.56 38.71±6.26 0.271 PT 13.51±14.61 12.09±1.74 0.44 APTT 40.05±24.27 30.56±4.99 0.003 INR 1.02±0.11 1.03±0.11 0.522 Ascites 2 (3.1%) 3 (4.7%) 0.648	Diabetes	7 (10.9%)	4 (6.3%)	0.344	
Hepatitis 1 (1.6%) 0 0.043 Child-Pugh score 5.25±0.69 5.13±0.49 0.239 Child-Pugh classification 0 0.239 Child-Pugh classification 0 0.239 A 59 (92.2%) 62 (96.9%) B 5 (7.8%) 2 (3.1%) AST 33.80±19.52 37.09±33.50 0.498 TBIL 16.53±16.47 18.95±32.47 0.596 Albumin 39.87±5.56 38.71±6.26 0.271 PT 13.51±14.61 12.09±1.74 0.44 APTT 40.05±24.27 30.56±4.99 0.003 INR 1.02±0.11 1.03±0.11 0.522 Ascites 2 (3.1%) 3 (4.7%) 0.648	CHD	7 (10.9%)	5 (7.8%)	0.544	
Child-Pugh score 5.25±0.69 5.13±0.49 0.239 Child-Pugh classification	Smoking	20 (31.3%)	26 (40.6.90%)	0.269	
Child-Pugh classification 59 (92.2%) 62 (96.9%) B 5 (7.8%) 2 (3.1%) AST 33.80±19.52 37.09±33.50 0.498 TBIL 16.53±16.47 18.95±32.47 0.596 Albumin 39.87±5.56 38.71±6.26 0.271 PT 13.51±14.61 12.09±1.74 0.44 APTT 40.05±24.27 30.56±4.99 0.003 INR 1.02±0.11 1.03±0.11 0.522 Ascites 2 (3.1%) 3 (4.7%) 0.648	Hepatitis	1 (1.6%)	0	0.043	
A 59 (92.2%) 62 (96.9%) B 5 (7.8%) 2 (3.1%) AST 33.80±19.52 37.09±33.50 0.498 TBIL 16.53±16.47 18.95±32.47 0.596 Albumin 39.87±5.56 38.71±6.26 0.271 PT 13.51±14.61 12.09±1.74 0.44 APTT 40.05±24.27 30.56±4.99 0.003 INR 1.02±0.11 1.03±0.11 0.522 Ascites 2 (3.1%) 3 (4.7%) 0.648	Child-Pugh score	5.25 ± 0.69	5.13 ± 0.49	0.239	
B 5 (7.8%) 2 (3.1%) AST 33.80±19.52 37.09±33.50 0.498 TBIL 16.53±16.47 18.95±32.47 0.596 Albumin 39.87±5.56 38.71±6.26 0.271 PT 13.51±14.61 12.09±1.74 0.44 APTT 40.05±24.27 30.56±4.99 0.003 INR 1.02±0.11 1.03±0.11 0.522 Ascites 2 (3.1%) 3 (4.7%) 0.648	Child-Pugh classification	n			
AST 33.80±19.52 37.09±33.50 0.498 TBIL 16.53±16.47 18.95±32.47 0.596 Albumin 39.87±5.56 38.71±6.26 0.271 PT 13.51±14.61 12.09±1.74 0.44 APTT 40.05±24.27 30.56±4.99 0.003 INR 1.02±0.11 1.03±0.11 0.522 Ascites 2 (3.1%) 3 (4.7%) 0.648	А	59 (92.2%)	62 (96.9%)		
TBIL 16.53 ± 16.47 18.95 ± 32.47 0.596 Albumin 39.87 ± 5.56 38.71 ± 6.26 0.271 PT 13.51 ± 14.61 12.09 ± 1.74 0.44 APTT 40.05 ± 24.27 30.56 ± 4.99 0.003 INR 1.02 ± 0.11 1.03 ± 0.11 0.522 Ascites $2(3.1\%)$ $3(4.7\%)$ 0.648	В	5 (7.8%)	2 (3.1%)		
Albumin 39.87±5.56 38.71±6.26 0.271 PT 13.51±14.61 12.09±1.74 0.44 APTT 40.05±24.27 30.56±4.99 0.003 INR 1.02±0.11 1.03±0.11 0.522 Ascites 2 (3.1%) 3 (4.7%) 0.648	AST	33.80 ± 19.52	37.09±33.50	0.498	
PT 13.51±14.61 12.09±1.74 0.44 APTT 40.05±24.27 30.56±4.99 0.003 INR 1.02±0.11 1.03±0.11 0.522 Ascites 2 (3.1%) 3 (4.7%) 0.648	TBIL	16.53 ± 16.47	18.95±32.47	0.596	
APTT 40.05±24.27 30.56±4.99 0.003 INR 1.02±0.11 1.03±0.11 0.522 Ascites 2 (3.1%) 3 (4.7%) 0.648	Albumin	39.87 ± 5.56	38.71 ± 6.26	0.271	
INR 1.02±0.11 1.03±0.11 0.522 Ascites 2 (3.1%) 3 (4.7%) 0.648	PT	13.51 ± 14.61	12.09 ± 1.74	0.44	
Ascites 2 (3.1%) 3 (4.7%) 0.648	APTT	40.05 ± 24.27	30.56 ± 4.99	0.003	
	INR	1.02 ± 0.11	1.03 ± 0.11	0.522	
RFA 8 (12.5%) 9 (14.1%) 0.795	Ascites	2 (3.1%)	3 (4.7%)	0.648	
	RFA	8 (12.5%)	9 (14.1%)	0.795	

Table 1. Comparison of baseline characteristics between the TACE (n = 64) and non-TACE (n = 64) groups before propensity score matching. Abbreviations: CHD, coronary heart disease; AST, aspartate aminotransferase; APTT, activated partial thromboplastin time; INR, international normalized ratio; RFA, Radiofrequency ablation. Data are shown as the mean \pm s.d. or number (%) of patients.

.....

The present retrospective study aimed to evaluate overall survival (OS) outcome in patients with or without TACE.

Results

Patient Characteristics before Propensity Score Matching. A total of 128 patients with unresectable hepatic metastases were included in the study; 64 patients (50%) were included in the TACE group and the remaining 64 were included in the non-TACE group.

The baseline characteristics of the TACE and non-TACE groups are summarized in Table 1. There were no significant differences between the two groups with respect to age, gender, primary tumour sites, other transfers, hypertension, diabetes, CHD, smoking, AST, PT, TBIL, albumin, Child-Pugh score, Child-Pugh classification,

Variables	TACE group	non-TACE group	<i>p</i> value
Age (years)	60.74 ± 9.57	58.38 ± 11.22	0.303
Gender, male	30 (71.4%)	26 (61.9%)	0.355
Primary tumour site			
Pancreas	6 (14.3%)	5 (11.9%)	0.977
Stomach	12 (28.6%)	11 (26.2%)	
Endometrium	0	0	
Chorion	0	0	
Colorectum	11 (26.2%)	11 (26.2%)	
Ovaries	1 (2.4%)	2 (4.8%)	
Bile ducts	2 (4.8%)	0	
Lung	3 (7.1%)	2 (4.8%)	
Kidney	0	1 (2.4%)	
Duodenum	2 (4.8%)	2 (4.8%)	
Breast	1 (2.4%)	2 (4.8%)	
Oesophagus	1 (2.4%)	2 (4.8%)	
Gallbladder	0	1 (2.4%)	
Others	3 (7.1%)	3 (7.1%)	
Numbers of hepatic me	tastases	8	
One	2 (4.8%)	6 (14.3%)	0.085
Two	0	2 (4.8%)	
More	30 (71.4%)	30 (71.4%)	
Unknown	10 (23.8%)	4 (9.5%)	
Other transfers	4		
Lymph gland	6 (14.3%)	11 (26.2%)	0.088
Other organs	6 (14.3%)	11 (26.2%)	
Unknown	30 (71.4%)	20 (47.6%)	
Hypertension	9 (21.4%)	10 (23.8%)	0.794
Diabetes	3 (7.1%)	2 (4.8%)	0.645
CHD	3 (7.1%)	3 (7.1%)	1
Smoking	16 (38.1%)	17 (40.5%)	0.823
Hepatitis	0	0	
Child-Pugh score	5.24±0.69	5.14 ± 0.57	0.492
Child-Pugh classification	n	1	1
А	38 (90.5%)	40 (95.2%)	0.676
В	4 (9.5%)	2 (4.8%)	
AST	32.14±19.25	39.19±38.80	0.295
TBIL	16.49 ± 17.66	22.53±39.63	0.369
Albumin	39.77±5.59	37.88±6.35	0.152
PT	14.20 ± 18.04	12.11 ± 1.79	0.456
APTT	30.12±3.13	29.69±3.20	0.536
INR	1.01 ± 0.10	1.04 ± 0.12	0.184
Ascites	0	1 (2.4%)	0.314
RFA	5 (11.9%)	5 (11.9%)	1

Table 2. Comparison of baseline characteristic between the TACE (n = 42) and non-TACE (n = 42) groups after propensity score matching. Abbreviations: CHD, coronary heart disease; AST, aspartate aminotransferase; APTT, activated partial thromboplastin time; INR, international normalized ratio; RFA, Radiofrequency ablation. Data are shown as the mean \pm s.d. or number (%) of patients.

.....

INR, ascites, and RFA. However, the numbers of hepatic metastases (p = 0.044), hepatitis (p = 0.043) and APTT (p = 0.003) were significantly different between the TACE and non-TACE groups.

Patient Characteristics after Propensity Score Matching. In the propensity score matched cohort, there were no significant differences between the two groups regarding age, gender, primary tumour site, numbers of hepatic metastases, other transfers, hepatitis, hypertension, diabetes, CHD, smoking, AST, PT, APTT, TBIL, albumin, Child-Pugh score, Child-Pugh classification, INR, ascites, and RFA. The results were showed in Table 2.




Figure 1. Kaplan-Meier analysis of OS between the two groups.

Viarables	Hazard Ratio (95% CI)	<i>p</i> value
Age	1.007 (0.982, 1.033)	0.585
C-P score	2.050 (0.575, 7.307)	0.268
C-P classification	3.319 (0.242, 45.535)	0.369
AST	1.010 (0.999, 1.021)	0.075
TBIL	1.001 (0.990, 1.013)	0.829
Albumin	0.968 (0.920, 1.019)	0.217
APTT	1.014 (0.935, 1.099)	0.739
INR	0.058 (0.005, 0.681)	0.023
RFA	3.054 (1.418, 6.579)	0.004
TACE	1.075 (0.625, 1.849)	0.795

Table 3. Cox proportional hazards multivariate regression analysis of OS. Cox proportional hazards multivariate regression analysis of overall survival.

OS After Propensity Score Matching. Kaplan-Meier survival analysis indicated no significant difference in median OS between the TACE and non-TACE groups (9, 95%CI: [6.29, 11.71]) vs. (8, 95%CI: [1.656, 14.344]) months, respectively; p = 0.789). Thus, TACE did not have a significant influence on OS. The result was showed in Fig. 1.

Multivariate analysis for the association of confounding factors with OS. To adjust for the simultaneous impact of potential confounders, Cox proportional hazards regression was performed (Table 3). In the univariate analysis, age, Child-Pugh score, Child-Pugh classification, AST, TBIL, albumin, APTT, INR and RFA were associated with OS. Multivariate analysis revealed that INR (HR 0.058, 95%CI: [0.005, 0.681]; p = 0.023) and RFA (HR 3.054, 95%CI: [1.418, 6.579]; p = 0.004) were independent risk factors for OS.

Discussion

The liver is the most common site metastasis from tumours that initially arise in colorectal cancer⁶. Twenty-five percent of the patients were diagnosed with liver metastases when they were found colorectal cancer. Surgery can improve the 5-year survival for resectable liver-only metastases of colorectal cancer^{7,8}. In a meta-analysis of observational studies, Luca Martella *et al.*⁹ found surgery showed a survival advantage for hepatic metastases of gastric cancer. However, many patients lose their chance for surgery when liver metastases are found. Our study researched patients with unresectable liver metastases; however, our patients' primary cancers were not limited to gastric and colorectal cancer.

In a study by Albert M. *et al.*¹⁰, TACE (with cisplatin, doxorubicin, mitomycin C, ethiodol and polyvinyl alcohol) for colorectal liver metastases provided local disease control of hepatic metastases after 43% of treatment cycles, with a median survival of 27 months overall. Their study included patients with unresectable liver metastases or recurrence after surgical resection. Hong K *et al.*¹¹ found that median survival times was 7.7 months for TACE. In our research, the primary cancer included pancreas, stomach, endometrium, colorectum, ovaries, bile duct, lung, kidney, duodenum, breast, oesophagus, jejunum, gallbladder, and mouth. Furthermore, we excluded




Figure 2. Flowchart of the study inclusion protocol.

patients who previously had local liver surgery. Patients were further excluded if the primary cancer was leukemia, lymphoma or melanoma.

We found that median OS was 9 months and 8 months in the TACE and non-TACE groups, respectively, and that there were no significant differences in either group (p = 0.789).

Gunduz S *et al.*¹² found that INR values reflecting the functional hepatic reserve can be used as a positive predictive factors for median hepatic progression-free survival with unresectable liver metastases. We found that INR could have a significant influence on the OS of unresectable liver metastases (p = 0.005).

Local ablative therapy for the treatment of metastatic liver disease has been evaluated most extensively in colorectal cancer with 5-year survival rates up to 55% after RFA⁶. Nielsen K *et al.*¹³ proved that RFA of colorectal liver metastases, after conversion chemotherapy, provides potential local control and good OS. Jakobs TF *et al.*¹⁴ proposed that RFA might improve survival for patients with unresectable hepatic metastases of colorectal cancer. In our research, we also proved that RFA was an effective means to alleviate unresectable liver metastases.

There are limitations to the present study due to its retrospective design. There were 22 patients who were not included in the matched cohort analysis in the TACE group. More patients for the non-TACE group were needed to match more pairs. Cancer-free survival, local recurrence, and adverse events should be investigated in the future.

In conclusion, our propensity matching score study suggests no significant difference in unresectable liver metastases with or without TACE. Further, INR and RFA can significantly affect OS of patients with unresectable liver metastases.

Methods

Patients. This retrospective cohort study included 171 hepatic metastases patients at Qilu hospital affiliated with Shandong University, Shandong, China and Shandong Provincial Hospital, Shandong, China from 2001 to 2015. The primary cancer sites of hepatic metastases included pancreas, stomach, endometrium, colorectum, ovaries, bile duct, lung, kidney, duodenum, breast, oesophagus, jejunum, gallbladder, and mouth. Patients who met any of the following criteria were excluded: (i) the primary cancer weas melanoma or a haemal tumour, (ii) liver cancer was the origin cancer, (iii) patients who underwent a liver resection, (iv) patients who underwent TACE therapy in other hospitals, (v) patients who refused further therapy after they were diagnosed with liver metastases, and (vi) patients who did not participate in the follow-up process. Based on these criteria, a total of 43 patients were excluded from the study. Of these, the primary cancer of 11 patients was melanoma or haemal tumour, 15 patients had undergone liver resections, 2 patients refused further therapy, 4 patients underwent TACE in other hospitals, 3 patients had liver cancer as the primary cancer, and 8 patients were did not participate in follow-up process. Finally, a total of 128 patients were included in our study.

To reduce the effects of selection bias and potential confounders in this study, we performed rigorous adjustment for differences in baseline characteristics by using propensity score matching. We considered age, gender, primary tumour sites, numbers of hepatic metastases, other transfers, hypertension, diabetes, coronary heart disease (CHD), smoking, hepatitis, Aspartate transaminase (AST), prothrombin time (PT), total bilirubin(T-BIL), albumin, Child-Pugh score, Child-Pugh classification, activated partial thromboplastin time (APTT), international normalized ratio(INR), ascites, and radiofrequency ablation (RFA). 42 patients' pairs were selected (Fig. 2). The study protocols were conducted in accordance with the Declaration of Helsinki and current ethical guidelines. Our study was approved by the Medical Ethics Committee of Shandong Provincial hospital and informed consent was obtained from all subjects.

Data collection and follow up. The following demographic, laboratory and clinical information was collected from medical chart review: age, gender, primary tumour sites, numbers of hepatic metastases, other transfers, hypertension, diabetes, CHD, smoking, hepatitis, AST, PT, TBIL, albumin, Child-Pugh score, Child-Pugh classification, APTT, INR, ascites, and RFA. Survival outcome and other patient information was obtained mostly by telephone follow-up. The survival time was defined from diagnosis of liver metastases to death or loss of follow-up.

Propensity Score Analysis. The propensity scores were estimated with all variables presented in Table 1 (baseline characteristics) using a parsimonious logistic regression model. We used the nearest neighbor matching algorithm without replacement. One to one¹⁵ calliper matching was performed within 25% of the standard deviation of the log-trans-formed propensity scores. The value of caliper was 0.5. In the propensity score-matched cohort, the two groups were compared in terms of baseline characteristics. The balance of the matched cohort was evaluated using standardized mean difference and hypothetical test. The Kaplan-Meier method with a log-rank test was applied to compare the survival distributions of patients. Cox proportional hazards regression was used to examine the association of TACE with survival rates by adjusting for the simultaneous impact of potential confounders. Multivariate analysis was performed on variables that were associated with survival rates based on univariate analysis (P < 0.05). Hazard ratios with 95% confidence intervals (CIs) were calculated.

Statistical Methods. In all study subjects, continuous variables were compared parametrically using Student's *t*-test or non-parametrically using the Mann-Whitney *U*-test. Categorical variables were compared using the χ^2 -test or Fisher's exact test as appropriate.

Statistical results are presented as the mean \pm s.d., and number of patients(%). Two-sided tests, *P* values < 0.05 were taken as significant. Statistical analyses were conducted using the IBM SPSS statistical package 22.0 (IBM, Armonk, NY, USA) with three plug-in (SPSS R-plug-in, R and psmatching).

References

- 1. Leporrier, J. et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. The British journal of surgery 93, 465–474, doi: 10.1002/bjs.5278 (2006).
- 2. Garden, O. J. *et al.* Guidelines for resection of colorectal cancer liver metastases. *Gut* 55 Suppl 3, iii1-8, doi: 10.1136/gut.2006.098053 (2006).
- Van Cutsem, E., Cervantes, A., Nordlinger, B. & Arnold, D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 25 Suppl 3, iii1-9, doi: 10.1093/annonc/mdu260 (2014).
- De Groote, K. & Prenen, H. Intrahepatic therapy for liver-dominant metastatic colorectal cancer. World journal of gastrointestinal oncology 7, 148–152, doi: 10.4251/wigo.v7.i9.148 (2015).
- Baek, S., Park, S. H., Won, E., Park, Y. R. & Kim, H. J. Propensity score matching: a conceptual review for radiology researchers. Korean journal of radiology 16, 286–296, doi: 10.3348/kjr.2015.16.2.286 (2015).
- Flanders, V. L. & Gervais, D. A. Ablation of liver metastases: current status. Journal of vascular and interventional radiology: JVIR 21, S214–S222, doi: 10.1016/j.jvir.2010.01.046 (2010).
- 7. Morris, E. J. *et al.* Surgical management and outcomes of colorectal cancer liver metastases. *The British journal of surgery* **97**, 1110–1118, doi: 10.1002/bjs.7032 (2010).
- de Jong, M. C. et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Annals of surgery 250, 440–448, doi: 10.1097/SLA.0b013e3181b4539b (2009).
- Martella, L. et al. Surgery for Liver Metastases From Gastric Cancer: A Meta-Analysis of Observational Studies. Medicine 94, e1113, doi: 10.1097/md.000000000001113 (2015).
- Albert, M. et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 117, 343–352, doi: 10.1002/cncr.25387 (2011).
- 11. Hong, K. *et al.* Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. *Journal of vascular and interventional radiology: JVIR* **20,** 360–367, doi: 10.1016/j.jvir.2008.11.019 (2009).
- 12. Gunduz, S. *et al.* Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy. *Hepato-gastroenterology* **61**, 1529–1534 (2014).
- Nielsen, K. et al. Radiofrequency Ablation to Improve Survival After Conversion Chemotherapy for Colorectal Liver Metastases. World journal of surgery, doi: 10.1007/s00268-016-3554-6 (2016).
- Jakobs, T. F., Hoffmann, R. T., Trumm, C., Reiser, M. F. & Helmberger, T. K. Radiofrequency ablation of colorectal liver metastases: mid-term results in 68 patients. Anticancer research 26, 671–680 (2006).
- Thoemmes, F. J. & Kim, E. S. A Systematic Review of Propensity Score Methods in the Social Sciences. *Multivariate behavioral research* 46, 90–118, doi: 10.1080/00273171.2011.540475 (2011).

Acknowledgements

We gratefully acknowledge Professor Cheng-yong Qin for his help in guiding and revising the manuscript. We also thank all of the study participants. This work was supported in part by the National Natural Science Foundation of China, grant number 81472685, the science and Technology Development Projects of Shandong Province, grant number 2013GSF11852, China Postdoctoral Science Foundation, grant number 2013M541926, the Postdoctoral Innovation Project Special Foundation of Shandong Province, grant number 201302031, the Promotive Research Fund for Excellent Young and Middle-aged Scientists of Shandong Province, grant number 812014YY37, National Natural Science Foundation of China, grant number 81600469, the Major Special Plan of

Science and Technology of Shandong Province, grant number 2015ZDXX0802A01, and the Promotive research fund for excellent young and middle-aged scientisits of Shandong Province, grant number BS2014YY037.

Author Contributions

F.Y.W., W.M., Y.L. and T.L. collected data and followed up with patients. F.Y.W. and Y.L. performed the statistical analysis. C.Y.Q. participated in the design of the review. All authors read and approved the final manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Fengyan, W. *et al.* Comparison of overall survival in patients with unresectable hepatic metastases with or without transarterial chemoembolization: A Propensity Score Matching Study. *Sci. Rep.* **6**, 35336; doi: 10.1038/srep35336 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016